Researcher Profile

Researcher Profile

Raymond Hohl, MD, PhD

Raymond Hohl, MD, PhD

University Professorship in Oncology, Department of Medicine
Professor, Department of Pharmacology
Scientific Program:Experimental Therapeutics
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
rjh35@psu.edu
View Website

Research Interests

  • Neoplasms
  • Terpenes
  • Therapeutics
  • Lovastatin
  • Proteins
  • Leukemia
  • Prenylation
  • Diphosphonates
  • Pharmacokinetics
  • Protein Prenylation
  • Farnesyltranstransferase
  • Cell Line

Clinical Trials

Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity

Recent Publications

2019

[C@280b8b09
[C@7fb5f309
[C@4766e01f
[C@300c0b28

2018

[C@2ce778c7
[C@2d3dac08
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, D, Helm, K, Drabick, J, Robertson, G, Neighbors, J, Hohl, R & Schell, T 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614. https://doi.org/10.1080/2162402X.2018.1539614
[C@2ced8649
[C@5be46f99

2017

[C@478ebe71
[C@746d57ce
[C@dbe6543
[C@3a8dac85

2016

[C@61ea39d
[C@43977ee6
[C@69afe741

2015

Kuder, CH, Weivoda, MM, Zhang, Y, Zhu, J, Neighbors, J, Wiemer, DF & Hohl, R 2015, '3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines' Lipids, vol. 50, no. 12, pp. 1195-1207. https://doi.org/10.1007/s11745-015-4083-z
[C@4516c618
Reilly, JE, Zhou, X, Tong, H, Kuder, CH, Wiemer, DF & Hohl, R 2015, 'In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors' Biochemical Pharmacology, vol. 96, no. 2, pp. 83-92. https://doi.org/10.1016/j.bcp.2015.04.009
Hohl, R 2015, 'Oncology trial design: More accurately and efficiently advancing the field', Clinical Pharmacology and Therapeutics, vol. 97, no. 5, pp. 430-432. https://doi.org/10.1002/cpt.94
Holstein, SA, Bigelow, JC, Olson, RD, Vestal, RE, Walsh, GM & Hohl, R 2015, 'Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors', Investigational New Drugs, vol. 33, no. 3, pp. 594-602. https://doi.org/10.1007/s10637-015-0220-z
Ferguson, NN, Thomas, CP, Hohl, R, Syrbu, SI, Stone, MS & Wanat, KA 2015, 'Primary cutaneous polymorphic ebv-associated posttransplant lymphoproliferative disorder after a renal transplant and review of the literature' American Journal of Dermatopathology, vol. 37, no. 10, pp. 790-794. https://doi.org/10.1097/DAD.0000000000000272
Reilly, JE, Neighbors, J, Tong, H, Henry, MD & Hohl, R 2015, 'Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis', Clinical and Experimental Metastasis, vol. 32, no. 6, pp. 555-566. https://doi.org/10.1007/s10585-015-9727-0
Osborn-Heaford, HL, Murthy, S, Gu, L, Larson-Casey, JL, Ryan, AJ, Shi, L, Glogauer, M, Neighbors, J, Hohl, R & Carter, AB 2015, 'Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis', Free Radical Biology and Medicine, vol. 86, pp. 47-56. https://doi.org/10.1016/j.freeradbiomed.2015.04.031

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)